Discover 3 European Penny Stocks With Market Caps Below €50M

European equities have recently been buoyed by a firmer risk appetite and resilient earnings, despite ongoing geopolitical volatility. For investors willing to explore beyond the major indices, penny stocks—often associated with smaller or newer companies—remain an intriguing area for potential growth. While the term "penny stocks" might seem outdated, these investments can still offer surprising value when supported by strong financial fundamentals and promising market positions.

Let's review some notable picks from our screened stocks.

Arterra Bioscience (BIT:ARBS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Arterra Bioscience S.p.A. is a research-based biotech company focused on the development of ingredients and natural solutions, with a market cap of €21.24 million.

Operations: The company generates its revenue primarily from its Specialty Chemicals segment, which accounts for €4.70 million.

Market Cap: €21.24M

Arterra Bioscience S.p.A., with a market cap of €21.24 million, has demonstrated strong financial health and growth potential, making it an interesting consideration among penny stocks. The company has achieved a significant earnings growth of 50.1% over the past year, surpassing both its five-year average and industry benchmarks. Its net profit margins have improved to 42.6%, and it maintains high-quality earnings with more cash than total debt, ensuring robust interest coverage. Additionally, Arterra's short-term assets exceed both short-term and long-term liabilities, reflecting solid financial management without shareholder dilution in the past year.

• Get an in-depth perspective on Arterra Bioscience's performance by reading our balance sheet health report here.
• Assess Arterra Bioscience's previous results with our detailed historical performance reports.

Navigo Invest (OM:NAVIGO STAM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Navigo Invest AB (publ) is a private equity and venture capital firm focusing on various investment stages such as buyouts, early stage, and growth capital, with a market cap of SEK518.99 million.

Operations: Navigo Invest's revenue is primarily derived from its segments: Chemgroup with SEK302.80 million, Vinga Group at SEK252.66 million, Calormet contributing SEK106.67 million, and The Geo Group generating SEK48.85 million.

Market Cap: SEK518.99M

Navigo Invest AB (publ), with a market cap of SEK518.99 million, has shown promising financial performance recently. The firm reported a net income of SEK20.83 million for Q2 2026, reversing a net loss from the previous year, and achieved revenue growth to SEK194.25 million from SEK150.81 million year-on-year. Its debt management is strong, with short-term assets exceeding liabilities and operating cash flow well covering its debt obligations at 28.3%. Despite low return on equity at 5.7%, Navigo's price-to-earnings ratio of 4.2x suggests it trades at good value compared to the Swedish market average of 19.5x.

• Take a closer look at Navigo Invest's potential here in our financial health report.
• Assess Navigo Invest's future earnings estimates with our detailed growth reports.

onesano (WSE:ONO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Onesano S.A. operates in Poland, focusing on the production of nutritional cycle products ranging from agricultural production and animal breeding to dietetics and human supplementation, with a market cap of PLN38.87 million.

Operations: The company's revenue is primarily derived from its Vitamins & Nutrition Products segment, which generated PLN13.16 billion.

Market Cap: PLN38.87M

Onesano S.A., with a market cap of PLN38.87 million, operates in the nutritional cycle sector but remains pre-revenue, generating PLN13.16 billion from its core Vitamins & Nutrition Products segment. Despite an improved financial position with positive shareholder equity and satisfactory net debt to equity ratio (22.8%), the company is unprofitable with a negative return on equity of -103.21%. Short-term assets cover both short- and long-term liabilities, yet Onesano faces a cash runway of less than one year if current free cash flow trends persist. Recent earnings show revenue growth to PLN3.49 million for Q1 2026, though net losses continue at PLN0.852 million compared to the previous year’s larger loss.

• Dive into the specifics of onesano here with our thorough balance sheet health report.
• Gain insights into onesano's historical outcomes by reviewing our past performance report.

Seize The Opportunity

• Click this link to deep-dive into the 303 companies within our European Penny Stocks screener.
• Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com